Company History

 

2010	August: Receives Ethics ('Helsinki') Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine July: Receives Frost & Sullivan '2010 European Influenza Vaccines Technology Innovation Award' June: Receives third annual consecutive grant from Israeli Office of Chief Scientist for $1 million towards the development of the Universal Influenza Vaccine April: Announced final safety and immunogenicity results from second Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains March: Announced positive interim safety results from the second Phase I/II trial in 60 elderly participants - the Multimeric-001 was found to be safe and well tolerated February: BiondVax signed a term sheet with Yorkville Advisers for the provision of a standby equity facility of up to $7m over three years
2009	December: BiondVax raised $5.3m in a secondary offering on the Tel Aviv Stock Exchange December: Announced immunogenicity results from first Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains October: Initiated subsequent Phase I/II trial in 60 healthy elderly volunteers August: Reported initial safety results from first Phase I/II trial - no significant adverse events found June: Initiated Phase I/II trial in 63 healthy adult volunteers February: Concluded GLP toxicology study
2008	November: Commenced a repeated (3 dose) GLP toxicology study using the maximal human dose July: Pre-IND Meeting.  BiondVax presented its pre- and clinical plans for the Multimeric-001 universal flu vaccine to the FDA in a Pre-IND meeting
2007	November: Voluntarily terminated first Phase I trial October: Avian flu study in collaboration with Israeli Veterianrian Institute July: Commenced Phase I clinical trial of 1st Generation vaccine June: IPO on the Tel Aviv Stock Exchange, raising about $3m
2006	Conducted pre-clinical and toxicology studies Production of 1st Generation vaccine
2005	Company operations begin Initial fundraising round completed
2004	Initial fundraising round commenced
2003	Signed a license agreement with the Weizmann Institute for the in-licensing to BiondVax of the patent relating to the Peptide-based Vaccine for Influenza BiondVax Pharmaceuticals Ltd. established as an Israeli company
1988 - 2002	15 years of R&D led by Prof. Ruth Arnon and her team at the Weizmann Institute of Science Established feasibility of Universal Peptide-based Influenza Vaccine in animals